he most common asthma inhaler for children was discontinued at the start of this year, forcing parents and pediatricians to scramble to switch to an alternative.
But more than a month later, the situation has not improved, and families remain caught in the middle of a fight between a drug company and pharmacy benefit managers (PBMs) with no end in sight.
Kommentare